Health · Pharma & Biotech · 1 hr ago

Onconic says OCN-501 preserved muscle in preclinical obesity-drug study

Onconic says OCN-501 preserved muscle in preclinical obesity-drug study

South Korea’s Onconic Therapeutics tested OCN-501 with semaglutide in a preclinical study.

Semaglutide is the active ingredient in Wegovy, an obesity treatment.

The company presented the findings at a US obesity conference in Washington, DC.

The combination group lost 15.3% of body weight, versus 13.1% with semaglutide alone, but that difference was not statistically significant.

Onconic said the combination improved muscle mass and limited loss of muscle strength compared with semaglutide alone.

This matters because the company aims to add muscle preservation to medicines used for obesity.

Onconic plans to develop OCN-501 as a combination treatment with incretin-based drugs such as Wegovy and Mounjaro; the candidate is still being studied before clinical use.

1 source

Related

What people are saying

Onconic representativeCompany representative
We plan to develop OCN-501 as a combination treatment that adds muscle-preserving function to incretin-based obesity drugs such as Wegovy and Mounjaro.
via Yonhap